Induced Pluripotent Stem Cell-Derived Neural Stem Cells Transduced with Baculovirus Encoding CD40 Ligand for Immunogene Therapy in Mouse Models of Breast Cancer
Restricted accessResearch articleFirst published online August, 2014
Induced Pluripotent Stem Cell-Derived Neural Stem Cells Transduced with Baculovirus Encoding CD40 Ligand for Immunogene Therapy in Mouse Models of Breast Cancer
The interaction between CD40 ligand (CD40L) and CD40 can directly inhibit growth of CD40-positive carcinoma cells and may indirectly inhibit tumor growth through coordination of immune responses. Many efforts in CD40L cancer gene therapy have been focused on direct CD40L gene transfer into malignant target cells. This in vivo gene therapy approach relies on high-efficiency gene transfer and could be technically challenging for the treatment of certain cancers, especially multisite metastases. We report herein an alternative means of using the tumor-homing property of neural stem cells (NSCs) to deliver CD40L molecules into tumor tissues. NSCs were derived from human induced pluripotent stem cells, transduced in vitro with a baculoviral vector encoding CD40L, and intravenously injected into immunocompetent mice with orthotopic and metastatic breast cancers. Through a bystander mechanism of intercellular transfer of CD40L from the donor NSCs to tumor target cells, the treatment impeded tumor growth, leading to prolonged survival of the tumor-bearing mice. We further showed that compared with the stem cell-based gene therapy that employed a suicide gene, the CD40L immunogene therapy did not cause liver and kidney injury in the treated mice. This new approach may be particularly valuable for metastatic cancer treatments after systemic stem cell administration.
Get full access to this article
View all access options for this article.
References
1.
AboodyK.S., BushR.A., GarciaE., et al. (2006). Development of a tumor-selective approach to treat metastatic cancer. PLoS One, 1, e23.
2.
AboodyK.S., NajbauerJ., and DanksM.K. (2008). Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther., 15, 739–752.
3.
AffordS.C., RandhawaS., EliopoulosA.G., et al. (1999). CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J. Exp. Med., 189, 441–446.
4.
AirenneK.J., HuY.C., KostT.A., et al. (2013). Baculovirus: An insect-derived vector for diverse gene transfer applications. Mol. Ther., 21, 739–749.
5.
BalaniP., BoulaireJ., ZhaoY., et al. (2009). High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol. Ther., 17, 1003–1011.
6.
BessisN., GarciacozarF.J., and BoissierM.C. (2004). Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther., 11(Suppl. 1), S10–S17.
7.
BiagiE., YvonE., DottiG., et al. (2003). Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum. Gene Ther., 14, 545–559.
8.
BinelloE., and GermanoI.M. (2012). Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro. Oncol., 14, 256–265.
9.
CheeverM.A. (2008). Twelve immunotherapy drugs that could cure cancers. Immunol. Rev., 222, 357–368.
10.
ChenC., WangY., GohS.S., et al. (2013). Inhibition of neuronal nitric oxide synthase activity promotes migration of human-induced pluripotent stem cell-derived neural stem cells toward cancer cells. J. Neurochem., 126, 318–330.
11.
CihovaM., AltanerovaV., and AltanerC. (2011). Stem cell based cancer gene therapy. Mol. Pharm., 8, 1480–1487.
12.
DanksM.K., YoonK.J., BushR.A., et al. (2007). Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res., 67, 22–25.
13.
DiaconuI., CerulloV., HirvinenM.L., et al. (2012). Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res., 72, 2327–2338.
14.
DongZ., and NorJ.E. (2009). Transcriptional targeting of tumor endothelial cells for gene therapy. Adv. Drug Deliv. Rev., 61, 542–553.
15.
DuJ., ZengJ., ZhaoY., et al. (2010). The combined use of viral transcriptional and post-transcriptional regulatory elements to improve baculovirus-mediated transient gene expression in human embryonic stem cells. J. Biosci. Bioeng., 109, 1–8.
16.
FernandesM.S., GomesE.M., ButcherL.D., et al. (2009). Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin. Cancer Res., 15, 4847–4856.
17.
FrankR.T., EdmistonM., KendallS.E., et al. (2009). Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One, 4, e8314.
18.
GalderisiU., GiordanoA., and PaggiM.G. (2010). The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J. Stem Cells, 2, 5–12.
19.
GomesE.M., RodriguesM.S., PhadkeA.P., et al. (2009). Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin. Cancer Res., 15, 1317–1325.
20.
HeimpelA.M., and BuchananL.K. (1967). Human feeding tests using a nuclear-polyhedrosis virus of Heliothis zea. J. Invertebr. Pathol., 9, 55–57.
21.
JoossK., and ChirmuleN. (2003). Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther., 10, 955–963.
22.
JurvansuuJ., ZhaoY., LeungD.S., et al. (2008). Transmembrane protein 18 enhances the tropism of neural stem cells for glioma cells. Cancer Res., 68, 4614–4622.
23.
KarmannK., HughesC.C., SchechnerJ., et al. (1995). CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. U.S.A., 92, 4342–4346.
24.
KarnoubA.E., DashA.B., VoA.P., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449, 557–563.
25.
KeungE.Z., NelsonP.J., and ConradC. (2013). Concise review: Genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy. Stem Cells, 31, 227–235.
26.
KloppA.H., GuptaA., SpaethE., et al. (2011). Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth?. Stem Cells, 29, 11–19.
27.
KimJ.H., KimJ.Y., KimS.U., et al. (2012). Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma. Biochem. Biophys. Res. Commun., 417, 534–540.
LeschH.P., MakkonenK.E., LaitinenA., et al. (2011). Requirements for baculoviruses for clinical gene therapy applications. J. Invertebr. Pathol., 107(Suppl.), S106–S112.
30.
LoskogA., and TottermanT.H. (2007). CD40L—a multipotent molecule for tumor therapy. Endocr. Metab. Immune Disord. Drug Targets, 7, 23–38.
31.
PhangR., TayF., GohS., et al. (2013). Zinc finger nuclease-expressing baculoviral vectors mediate targeted genome integration of reprogramming factor genes to facilitate the generation of human induced pluripotent stem cells. Stem Cells Transl. Med., 2, 935–945.
32.
RamachandraC.J., ShahbaziM., KwangT.W., et al. (2011). Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors. Nucleic Acids Res., 39, e107.
33.
ShahK. (2012). Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev., 64, 739–748.
34.
StraussR., HuserA., NiS., et al. (2007). Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol. Ther., 15, 193–202.
35.
TangY., ShahK., MesserliS.M., et al. (2003). In vivo tracking of neural progenitor cell migration to glioblastomas. Hum. Gene Ther., 14, 1247–1254.
36.
TayF.C., TanW.K., GohS.L., et al. (2013). Targeted transgene insertion into the AAVS1 locus driven by baculoviral vector-mediated zinc finger nuclease expression in human induced pluripotent stem cells. J. Gene Med., 15, 384–395.
37.
ThienelU., LoikeJ., and YellinM.J. (1999). CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol., 198, 87–95.
38.
TongA.W., and StoneM.J. (2003). Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther., 10, 1–13.
39.
UllenhagG., and LoskogA.S. (2012). AdCD40L—crossing the valley of death?. Int. Rev. Immunol., 31, 289–298.
40.
YangJ., LamD.H., GohS.S., et al. (2012). Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells, 30, 1021–1029.
41.
ZengJ., DuJ., LinJ., et al. (2009). High-efficiency transient transduction of human embryonic stem cell-derived neurons with baculoviral vectors. Mol. Ther., 17, 1585–1593.
42.
ZhaoD., NajbauerJ., AnnalaA.J., et al. (2012). Human neural stem cell tropism to metastatic breast cancer. Stem Cells, 30, 314–325.
43.
ZhaoY., and WangS. (2010). Human NT2 neural precursor-derived tumor-infiltrating cells as delivery vehicles for treatment of glioblastoma. Gene Ther., 21, 683–694.
44.
ZhuD., LamD.H., PurwantiY.I., et al. (2013). Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells. Mol. Ther., 21, 1621–1630.
45.
ZhuH., LauC.H., GohS.L., et al. (2013). Baculoviral transduction faciliates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human induced pluripotent stem cells. Nucleic Acids Res., 41, e180.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
